EGFR and pancreatic neoplasm: A phase III trial treating 745 patients with advanced/metastatic pancreatic cancer (90% EGFR positive) with gemcitabine alone or gemcitabine plus cetuximab, demonstrated no significant differences in response, median survival or PFS.